HK1036801A1 - Pyrrolo(2,3-d)pyrimidine compounds, composition and use there of - Google Patents

Pyrrolo(2,3-d)pyrimidine compounds, composition and use there of

Info

Publication number
HK1036801A1
HK1036801A1 HK01107744A HK01107744A HK1036801A1 HK 1036801 A1 HK1036801 A1 HK 1036801A1 HK 01107744 A HK01107744 A HK 01107744A HK 01107744 A HK01107744 A HK 01107744A HK 1036801 A1 HK1036801 A1 HK 1036801A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolo
composition
pyrimidine compounds
pyrimidine
compounds
Prior art date
Application number
HK01107744A
Other languages
English (en)
Inventor
Todd Andrew Blumenkopf
Mark Edward Flanagan
Matthew Frank Brown
Paul Steven Changelian
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26781018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1036801(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HK1036801A1 publication Critical patent/HK1036801A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK01107744A 1998-06-19 2001-11-06 Pyrrolo(2,3-d)pyrimidine compounds, composition and use there of HK1036801A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8986698P 1998-06-19 1998-06-19
US10478798P 1998-10-19 1998-10-19
PCT/IB1999/001100 WO1999065908A1 (en) 1998-06-19 1999-06-14 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS

Publications (1)

Publication Number Publication Date
HK1036801A1 true HK1036801A1 (en) 2002-01-18

Family

ID=26781018

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01107744A HK1036801A1 (en) 1998-06-19 2001-11-06 Pyrrolo(2,3-d)pyrimidine compounds, composition and use there of

Country Status (41)

Country Link
US (3) US6610847B2 (ru)
EP (1) EP1087970B1 (ru)
JP (3) JP4666762B2 (ru)
KR (1) KR100415791B1 (ru)
CN (1) CN1128800C (ru)
AP (1) AP1021A (ru)
AR (1) AR016499A1 (ru)
AT (1) ATE265458T1 (ru)
AU (1) AU3951899A (ru)
BG (1) BG65119B1 (ru)
BR (1) BR9911365A (ru)
CA (1) CA2335492C (ru)
CZ (1) CZ20004727A3 (ru)
DE (1) DE69916833T2 (ru)
DK (1) DK1087970T3 (ru)
EA (1) EA005852B1 (ru)
ES (1) ES2219018T3 (ru)
FR (1) FR14C0019I2 (ru)
GE (1) GEP20074227B (ru)
GT (1) GT199900090A (ru)
HK (1) HK1036801A1 (ru)
HR (1) HRP20000885B1 (ru)
HU (1) HUP0102574A3 (ru)
ID (1) ID26698A (ru)
IL (1) IL139586A0 (ru)
MA (1) MA26654A1 (ru)
MY (1) MY125916A (ru)
NO (1) NO318784B1 (ru)
NZ (1) NZ518444A (ru)
OA (1) OA11572A (ru)
PA (1) PA8476001A1 (ru)
PE (1) PE20000698A1 (ru)
PL (1) PL198640B1 (ru)
PT (1) PT1087970E (ru)
RS (1) RS50087B (ru)
SA (1) SA99200283B1 (ru)
SK (1) SK286640B6 (ru)
TN (1) TNSN99126A1 (ru)
TR (1) TR200003719T2 (ru)
TW (1) TW505646B (ru)
WO (1) WO1999065908A1 (ru)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087970B1 (en) * 1998-06-19 2004-04-28 Pfizer Products Inc. PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
CN100351253C (zh) * 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
AU2001293817A1 (en) 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
US7067550B2 (en) * 2000-11-03 2006-06-27 Massachusetts Institute Of Technology Treatments for neurotoxicity in Alzheimer's Disease
DE10063294A1 (de) * 2000-12-19 2002-07-04 Aventis Pharma Gmbh Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2436487A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
ATE305303T1 (de) 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003002106A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitions for treating allergic diseases
WO2003003006A2 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
ATE330608T1 (de) 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
CA2452392A1 (en) 2001-06-29 2003-01-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
ATE401079T1 (de) * 2001-06-29 2008-08-15 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
ES2305435T3 (es) * 2002-01-10 2008-11-01 Bayer Healthcare Ag Inhibidores de la rho-quinasa.
US6943172B2 (en) 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
CA2473510A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
JP2006509000A (ja) 2002-11-26 2006-03-16 ファイザー・プロダクツ・インク 移植片拒絶反応の処置の方法
CA2543116A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
JP2007512316A (ja) * 2003-11-25 2007-05-17 ファイザー・プロダクツ・インク アテローム性動脈硬化症の治療方法
AU2005227997A1 (en) * 2004-03-30 2005-10-13 Arena Pharmaceuticals, Inc. Pyrimidine derivatives and methods of treatment related to the use thereof
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
EP1768982A2 (en) 2004-06-29 2007-04-04 Amgen Inc. Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity
EP1797054A2 (en) 2004-08-02 2007-06-20 OSI Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
ATE492545T1 (de) 2005-05-13 2011-01-15 Irm Llc Verbindungen und zusammensetzungen als proteinkinase-hemmer
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
US8580802B2 (en) * 2005-09-30 2013-11-12 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases
ES2612196T3 (es) 2005-12-13 2017-05-12 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
EA200870385A1 (ru) * 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. Ингибирование токсичности альфа-синуклеина
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
TW200900061A (en) 2007-01-12 2009-01-01 Astellas Pharma Inc Condensed pyridine compound
JP2010523522A (ja) * 2007-04-02 2010-07-15 パラウ・フアルマ・ソシエダツド・アノニマ Ｊａｋ３阻害剤としてのピロロピリミジン誘導体
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
MX342814B (es) 2007-06-13 2016-10-13 Incyte Holdings Corp Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
DE102007027800A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
CN102007504A (zh) * 2007-11-10 2011-04-06 兰德马克绘图国际公司，哈里伯顿公司 工作流程自动化、自适应和集成的系统及方法
EP3912973A3 (en) * 2007-11-28 2022-02-16 Dana-Farber Cancer Institute, Inc. Small molecule myristate inhibitors of bcr-abl and methods of use
BRPI0908433A2 (pt) 2008-02-06 2019-09-24 Novartis Ag pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase
CA2713710A1 (en) * 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
MX2010010012A (es) 2008-03-11 2010-10-20 Incyte Corp Derivados de azetidina y ciclobutano como inhibidores de jak.
WO2009115084A2 (de) * 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
CA2728559A1 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
WO2010014930A2 (en) * 2008-08-01 2010-02-04 Biocryst Pharmaceuticals, Inc. Therapeutic agents
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
US8385364B2 (en) * 2008-09-24 2013-02-26 Nec Laboratories America, Inc. Distributed message-passing based resource allocation in wireless systems
ES2552805T3 (es) 2009-04-20 2015-12-02 Auspex Pharmaceuticals, Llc Inhibidores piperidínicos de la cinasa Janus 3
CA2762174C (en) 2009-05-22 2018-02-20 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR20120030447A (ko) 2009-05-22 2012-03-28 인사이트 코포레이션 Ｊａｋ 저해물질로서 ３-［４-（７ｈ-피롤로［２,３-ｄ］피리미딘-４-일）-１ｈ-피라졸-１-일］옥탄- 또는 헵탄-니트릴
WO2011003418A1 (en) 2009-07-08 2011-01-13 Leo Pharma A/S Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
AP2012006192A0 (en) * 2009-10-15 2012-04-30 Pfizer PyrroloÄ2,3-DÜ pyrimidine compounds.
ES2461967T3 (es) 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
AU2011213198B2 (en) 2010-02-05 2014-04-24 Zoetis Llc Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors
EP2360158A1 (en) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
RS60680B1 (sr) 2010-03-10 2020-09-30 Incyte Holdings Corp Piperidin-4-il azetidin derivati kao inhibitori jak1
RU2013105450A (ru) * 2010-07-09 2014-08-20 Лео Фарма А/С Новые производные гомопиперзина в качестве ингибиторов протеинтирозинкиназ и их фармацевтическое применение
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
TW201249845A (en) 2010-11-19 2012-12-16 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
AU2012204843A1 (en) 2011-01-07 2013-05-02 Leo Pharma A/S Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
MX357939B (es) 2011-02-18 2018-07-31 Novartis Pharma Ag Terapia de combinacion de inhibidor de objetivo de rapamicina en mamifero/janus cinasa (mtor/jak).
BR112013024267A2 (pt) 2011-03-22 2018-06-26 Advinus Therapeutics Ltd compostos tricíclicos fundidos substituídos, composições e aplicações medicinais dos mesmos.
JP2014513728A (ja) * 2011-05-17 2014-06-05 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤としてのアザインドール誘導体
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
BR112014013224B1 (pt) * 2011-11-30 2023-03-07 Emory University Inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais
JP6075736B2 (ja) * 2011-12-21 2017-02-08 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピロール−６員ヘテロアリール環誘導体、その合成法およびその医薬用途
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
US9296757B2 (en) 2012-05-21 2016-03-29 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
AP3902A (en) * 2012-06-29 2016-11-17 Pfizer Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
JO3384B1 (ar) * 2012-07-17 2019-03-13 Glaxosmithkline Ip No 2 Ltd مركبات إندول كربونيتريل في صورة معدلات لمستقبل أندروجين انتقائية
DK2874630T3 (en) 2012-07-20 2019-01-28 Zoetis Services Llc Dosage regimen for Janus kinase (JAK) inhibitors
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
IN2015DN02008A (ru) 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
CN102936251A (zh) * 2012-11-05 2013-02-20 上海毕得医药科技有限公司 一种吡咯并[2,3-d]嘧啶衍生物的制备方法
RS62329B1 (sr) 2012-11-15 2021-10-29 Incyte Holdings Corp Dozni oblici ruksolitiniba sa produženim vremenom oslobađanja
KR101683061B1 (ko) * 2013-02-07 2016-12-07 한국과학기술연구원 ＪＡＫ-3 저해제로 유용한 ７Ｈ-피롤로[2,3-ｄ]피리미딘-4-싸이올 유도체
RS56503B1 (sr) 2013-02-22 2018-02-28 Pfizer Derivati pirolo [2,3-d] pirimidina kao inhibitori janus kinaza (jak)
ES2900492T3 (es) 2013-03-06 2022-03-17 Incyte Holdings Corp Procesos y productos intermedios para elaborar un inhibidor de JAK
WO2014139388A1 (en) * 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EA201690357A1 (ru) 2013-08-07 2016-07-29 Инсайт Корпорейшн Лекарственные формы с замедленным высвобождением для ингибитора jak1
PT3077395T (pt) 2013-12-05 2018-01-03 Pfizer Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo e pirrolo[2,3-d]piridinilo acrilamidas
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
ES2750655T3 (es) 2014-08-12 2020-03-26 Pfizer Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
WO2016178110A1 (en) 2015-05-01 2016-11-10 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
PT3305788T (pt) * 2015-05-29 2020-09-25 Wuxi Fortune Pharmaceutical Co Ltd Inibidor da janus cinase
KR101771219B1 (ko) 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
CN106831779B (zh) * 2015-11-28 2019-07-19 南昌弘益药业有限公司 一类jak激酶抑制剂的新化合物
JP6568324B2 (ja) 2016-02-16 2019-08-28 ゾエティス・サービシーズ・エルエルシー ７Ｈ−ピロロ［２，３−ｄ］ピリミジン化合物の調製方法
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
DK3555074T3 (da) 2016-12-14 2022-10-03 Intervet Int Bv Aminopyrazoler som selektive januskinasehæmmere
KR20210072125A (ko) * 2018-11-05 2021-06-16 아비스타 파마 솔루션즈, 아이엔씨. 화합물
TW202043205A (zh) * 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
CA3125350A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
WO2020198583A1 (en) 2019-03-27 2020-10-01 Insilico Medicine Ip Limited Bicyclic jak inhibitors and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN117242080A (zh) 2020-12-18 2023-12-15 勃林格殷格翰动物保健美国公司 含硼吡唑化合物、包括其的组合物、其方法和用途
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
WO2023029943A1 (zh) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 一种芳杂环化合物及其制备方法和用途
WO2023055731A1 (en) * 2021-09-28 2023-04-06 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
AU2022418280A1 (en) 2021-12-24 2024-06-13 Intervet International B.V. Use of aminopyrazole compounds
GB202215117D0 (en) * 2022-10-13 2022-11-30 Norwegian Univ Sci & Tech Ntnu Compound
GB202215132D0 (en) * 2022-10-13 2022-11-30 Norwegian Univ Sci & Tech Ntnu Compound

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915304A (en) 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DK0682027T3 (da) 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
CA2223081C (en) * 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
EP0836602B1 (en) 1995-07-05 2002-01-30 E.I. Du Pont De Nemours And Company Fungicidal pyrimidinones
MX9800215A (es) * 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
PL321296A1 (en) 1995-11-14 1997-12-08 Pharmacia & Upjohn Spa Derivatives of aryl and heteroaryl purine
DE69712745T2 (de) 1996-01-23 2002-10-31 Novartis Ag Pyrrolopyrimidinen und verfahren zu deren herstellung
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
WO1997032879A1 (de) 1996-03-06 1997-09-12 Novartis Ag 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
TR199900048T2 (xx) 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AU720429B2 (en) 1996-08-23 2000-06-01 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
CN1237177A (zh) * 1996-11-27 1999-12-01 辉瑞大药厂 稠合的二环嘧啶衍生物
JP2001509805A (ja) 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
AU6568398A (en) 1997-03-24 1998-10-20 Pharmacia & Upjohn Company Method for identifying inhibitors of jak2/cytokine receptor binding
US6080847A (en) * 1997-12-04 2000-06-27 Incyte Pharmaceuticals, Inc. Proteins associated with cell proliferation
EP1068206A1 (en) 1998-04-02 2001-01-17 Neurogen Corporation Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors
AU4317399A (en) 1998-05-28 1999-12-13 Parker Hughes Institute Quinazolines for treating brain tumor
EP1087970B1 (en) * 1998-06-19 2004-04-28 Pfizer Products Inc. PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
WO2000000202A1 (en) 1998-06-30 2000-01-06 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
ATE292121T1 (de) 1998-08-21 2005-04-15 Parker Hughes Inst Chinazolinderivate
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
CN100351253C (zh) * 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
AU2009100870A4 (en) 2008-10-01 2009-10-22 Rock Tone Enterprise Co., Ltd. Drive mechanism for dehydrator
TWM358618U (en) 2008-12-26 2009-06-11 Rock Tone Entpr Co Ltd Combination structure of mop holder and cleaning body

Also Published As

Publication number Publication date
DE69916833D1 (de) 2004-06-03
PE20000698A1 (es) 2000-08-19
MY125916A (en) 2006-08-30
AP1021A (en) 2001-11-09
OA11572A (en) 2004-07-01
JP4666762B2 (ja) 2011-04-06
EP1087970B1 (en) 2004-04-28
BR9911365A (pt) 2001-03-13
ES2219018T3 (es) 2004-11-16
NO20006453L (no) 2001-02-05
KR100415791B1 (ko) 2004-01-24
TW505646B (en) 2002-10-11
AU3951899A (en) 2000-01-05
PA8476001A1 (es) 2003-09-05
HUP0102574A2 (hu) 2001-11-28
SK18982000A3 (sk) 2002-08-06
SK286640B6 (sk) 2009-03-05
US6610847B2 (en) 2003-08-26
MA26654A1 (fr) 2004-12-20
CN1305480A (zh) 2001-07-25
AP9901584A0 (en) 1999-06-30
KR20010053004A (ko) 2001-06-25
NO318784B1 (no) 2005-05-09
BG65119B1 (bg) 2007-03-30
AR016499A1 (es) 2001-07-04
PL198640B1 (pl) 2008-07-31
EA005852B1 (ru) 2005-06-30
WO1999065908A1 (en) 1999-12-23
ATE265458T1 (de) 2004-05-15
EP1087970A1 (en) 2001-04-04
CZ20004727A3 (cs) 2002-03-13
US20020019526A1 (en) 2002-02-14
CN1128800C (zh) 2003-11-26
NO20006453D0 (no) 2000-12-18
CA2335492C (en) 2005-05-17
HRP20000885A2 (en) 2001-10-31
HUP0102574A3 (en) 2002-01-28
JP2012041365A (ja) 2012-03-01
IL139586A0 (en) 2002-02-10
SA99200283B1 (ar) 2006-03-25
EA200001203A1 (ru) 2001-06-25
HRP20000885B1 (en) 2007-03-31
JP4971068B2 (ja) 2012-07-11
DE69916833T2 (de) 2005-04-14
US20050171128A1 (en) 2005-08-04
TR200003719T2 (tr) 2001-03-21
GT199900090A (es) 2000-12-09
NZ518444A (en) 2004-04-30
PL345123A1 (en) 2001-12-03
YU78500A (sh) 2003-04-30
BG105129A (en) 2001-11-30
CA2335492A1 (en) 1999-12-23
FR14C0019I2 (fr) 2015-01-02
ID26698A (id) 2001-02-01
FR14C0019I1 (ru) 2014-04-11
PT1087970E (pt) 2004-06-30
JP2007284455A (ja) 2007-11-01
GEP20074227B (en) 2007-10-25
RS50087B (sr) 2009-01-22
US20030212273A1 (en) 2003-11-13
US7687507B2 (en) 2010-03-30
US6890929B2 (en) 2005-05-10
TNSN99126A1 (fr) 2005-11-10
DK1087970T3 (da) 2004-08-02
JP2002518393A (ja) 2002-06-25

Similar Documents

Publication Publication Date Title
HK1036801A1 (en) Pyrrolo(2,3-d)pyrimidine compounds, composition and use there of
HK1036800A1 (en) Pyrrolo(2,3-d)pyrimidine compounds, its composition and use thereof
HUP0103836A3 (en) Pyrrolo[2,3d]pyrimidine compositions and their use
PT1382339E (pt) Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
HUP0102187A3 (en) Azolo triazines and pyrimidines, pharmaceutical compositions containing them and use of the compounds
IL143232A0 (en) Novel triazolo (4,5-d) pyrimidine compounds
HUP0301114A3 (en) Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them
HK1018439A1 (en) 5h-thiazolo (3,2-a) pyrimidine derivatives
HUP0100328A3 (en) Novel triazolo(4,5-d)pyrimidine compounds, and pharmaceutical compositions containing the compounds
AU5491699A (en) Process for the preparation of pyrrolo(2,3-d)pyrimidines
IL131618A0 (en) 5,7-Disubstituted aminopyrido [2,3-D] pyrimidine compounds and their use as adenosine kinase inhibitors
HUP0001698A3 (en) Substituted pyrimidine compounds and their use
IL150163A (en) PHARMACEUTICAL COMPOSITIONS COMPRISING PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND SOME NOVEL SUCH COMPOUNDS
PL361890A1 (en) Use of pyrazolo[4,3-d]pyrimidines
IL131892A0 (en) 6, 7-Disubstituted-4-aminopyrido [2, 3-d] pyrimidine compounds
ZA983175B (en) 5, 6, 7-Trisubstituted-4-aminopyrido (2, 3-d) pyrimidine compounds
SI1087970T1 (en) PYRROLO 2,3-d)PYRIMIDINE COMPOUNDS

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20190613